Your browser doesn't support javascript.
loading
Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.
Numao, Shin; Hasler, Franziska; Laguerre, Claire; Srinivas, Honnappa; Wack, Nathalie; Jäger, Petra; Schmid, Andres; Osmont, Arnaud; Röthlisberger, Patrik; Houguenade, Jeremy; Bergsdorf, Christian; Dawson, Janet; Carte, Nathalie; Hofmann, Andreas; Markert, Christian; Hardaker, Liz; Billich, Andreas; Wolf, Romain M; Penno, Carlos A; Bollbuck, Birgit; Miltz, Wolfgang; Röhn, Till A.
Afiliación
  • Numao S; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Hasler F; Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Laguerre C; Analytical Sciences & Imaging, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Srinivas H; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Wack N; Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Jäger P; Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Schmid A; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Osmont A; Analytical Sciences & Imaging, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Röthlisberger P; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Houguenade J; Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Bergsdorf C; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Dawson J; Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Carte N; Analytical Sciences & Imaging, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Hofmann A; Analytical Sciences & Imaging, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Markert C; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Hardaker L; Respiratory Research, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Billich A; Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Wolf RM; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Penno CA; Analytical Sciences & Imaging, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Bollbuck B; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Miltz W; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Röhn TA; Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. till.roehn@novartis.com.
Sci Rep ; 7(1): 13591, 2017 10 19.
Article en En | MEDLINE | ID: mdl-29051536

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Oligopéptidos / Prolina / Inhibidores Enzimáticos / Epóxido Hidrolasas Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Oligopéptidos / Prolina / Inhibidores Enzimáticos / Epóxido Hidrolasas Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article